BioVie's Lead Compound BIV201 Receives FDA Orphan-Drug Designation for the Treatment of Ascites

BEVERLY, MA--(Healthcare Sales & Marketing Network) - BioVie Inc. (OTC PINK: BIVI) (the "Company"), a development-stage company focused on the discovery, development, and commercialization of innovative drug therapies, announced today that the Fo... Biopharmaceuticals, FDA BioVie, ascites, cirrhosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news